Indication-specific dosing for humulus lupulus (hops), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.

Sections

Sections Hops
Suggested Dosing
Suggested Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology

Suggested Dosing

Insomnia

Dried strobile: 1.5-2 g

Extract combo with valerian: 60 mg

Suggested Uses

Anxiety, insomnia & other sleep disorders, restlessness, tension, excitability, ADHD, nervousness, and irritability

Efficacy

Possibly effective for mild sedation

Interaction Checker

Enter a drug name and Hops

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Contraindicated (0)

Serious - Use Alternative (0)

Monitor Closely (25)

amobarbital
hops increases effects of amobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
azelastine
hops increases effects of azelastine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
brompheniramine
hops increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
butabarbital
hops increases effects of butabarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
butalbital
hops increases effects of butalbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
carbinoxamine
hops increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
chloral hydrate
hops increases effects of chloral hydrate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
chlorpheniramine
hops increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
cinnarizine
hops increases effects of cinnarizine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
clemastine
hops increases effects of clemastine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
cyclizine
hops increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
cyproheptadine
hops increases effects of cyproheptadine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
dexchlorpheniramine
hops increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
dexmedetomidine
hops increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
dimenhydrinate
hops increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
diphenhydramine
hops increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
doxylamine
hops increases effects of doxylamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
hydroxyzine
hops increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
pentobarbital
hops increases effects of pentobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
phenobarbital
hops increases effects of phenobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
primidone
hops increases effects of primidone by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
promethazine
hops increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
secobarbital
hops increases effects of secobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
triclofos
hops increases effects of triclofos by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
triprolidine
hops increases effects of triprolidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

Minor (0)

amobarbital
Monitor Closely (1)hops increases effects of amobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
azelastine
Monitor Closely (1)hops increases effects of azelastine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
brompheniramine
Monitor Closely (1)hops increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
butabarbital
Monitor Closely (1)hops increases effects of butabarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
butalbital
Monitor Closely (1)hops increases effects of butalbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
carbinoxamine
Monitor Closely (1)hops increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
chloral hydrate
Monitor Closely (1)hops increases effects of chloral hydrate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
chlorpheniramine
Monitor Closely (1)hops increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
cinnarizine
Monitor Closely (1)hops increases effects of cinnarizine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
clemastine
Monitor Closely (1)hops increases effects of clemastine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
cyclizine
Monitor Closely (1)hops increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
cyproheptadine
Monitor Closely (1)hops increases effects of cyproheptadine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
dexchlorpheniramine
Monitor Closely (1)hops increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
dexmedetomidine
Monitor Closely (1)hops increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
dimenhydrinate
Monitor Closely (1)hops increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
diphenhydramine
Monitor Closely (1)hops increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
doxylamine
Monitor Closely (1)hops increases effects of doxylamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
hydroxyzine
Monitor Closely (1)hops increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
pentobarbital
Monitor Closely (1)hops increases effects of pentobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
phenobarbital
Monitor Closely (1)hops increases effects of phenobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
primidone
Monitor Closely (1)hops increases effects of primidone by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
promethazine
Monitor Closely (1)hops increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
secobarbital
Monitor Closely (1)hops increases effects of secobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
triclofos
Monitor Closely (1)hops increases effects of triclofos by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
triprolidine
Monitor Closely (1)hops increases effects of triprolidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

Frequency Not Defined

Contact dermatitis

Contraindications

N/A

Pregnancy & Lactation

Pregnancy Category: N/A

Lactation: N/A

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Pharmacology

Metabolism: N/A

Excretion: N/A

Mechanism of Action

2-methyl-3-butene-2-ol has sedative properties

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]